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Rebelo et al., p. 597
Aberrant protein aggregation is a cardinal feature of
many neurodegenerative diseases. Although the origins
of these protein aggregates are diverse, many form
insoluble fibrils termed amyloids, and the outcome is
often toxicity. In this issue, Rebelo et al. describe a class
of mutations—causing frameshifts and extensions into
what should be the 30 UTR—that promote amyloid for-
mation in the resultant proteins. The authors found
these types of mutations in two neurofilament genes,
NFEH and NFEL, as well as in FUS. Expression of the
variant neurofilaments in cell culture altered cellular
morphology, and injection of zebrafish with mutant
mRNAs disrupted motor neuron development. More-
over, an in silico analysis led the authors to suggest
that this pattern might be widespread: over 4,000 genes
contained 30 UTR sequences that, if translated, would
be prone to aggregation. Fortunately, mutations required
to generate cryptic amyloidogenic elements are prob-
ably rare: not only would they need to occur near the
end of the gene, but they would also have to allow for
translation in the appropriate reading frame. Further
investigation will be required for determining whether
any of these genes are altered in human disease, but
the findings from Rebelo et al. serve as a reminder that
pathogenicity can arise outside of the typical coding
region.SMG9 Mutations in Mice and Men
Shaheen et al., p. 643
Nonsense-mediated decay (NMD) is a global surveillance
mechanism that eliminates transcripts harboring prema-
ture termination codons (PTCs), thereby reducing errors
in gene expression. It stands to reason, then, that muta-
tions affecting key components of the NMD pathway
could result in severe, and possibly multisystemic, phe-
notypes. In this issue, Shaheen et al. identified homozy-
gous mutations in SMG9, whose protein product is
thought to be essential for NMD, in two families affected
by similar patterns of congenital anomalies. Disruption
of Smg9 in mice reduced viability and recapitulated
many of the phenotypes observed in humans, albeit1Deputy Editor, AJHG
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to better understand the underlying molecular changes
in individuals harboring SMG9 mutations. Somewhat
unexpectedly, transcripts harboring the identified SMG9
mutations generated PTCs, and SMG9 was not produced
in cells derived from an affected individual. Moreover,
although global transcriptional patterns were altered,
NMD appeared to be intact in cells derived from an
affected individual. The mechanism by which NMD con-
tinues to function in these cells remains unclear, but
compensation from other members of the NMD pathway
seems a plausible explanation.Maternal Smoking Elicits Major Methylation
Changes
Joubert et al., p. 680
Smoking is bad for you. We all know this, but as for
many addictive habits, quitting can be very difficult. In
addition to the fact that health complications can arise
in smokers, a substantial body of work points to the
negative consequences of maternal smoking for a devel-
oping fetus. However, despite the risks brought forth
by maternal smoking (e.g., low birth weight, reduced
pulmonary function, and asthma), the underlying mo-
lecular mechanisms remain incompletely understood.
Although recent studies have begun to explore the
possible role of epigenetic modification in this process,
limitations of technology and cohort size have made
it difficult to draw strong conclusions. In this issue,
Joubert et al. performed an epigenome-wide meta-anal-
ysis on 13 birth cohort studies to take an in-depth look
at the association between maternal smoking and
DNA methylation in offspring. The authors identified
thousands of differentially methylated CpGs in the
offspring of mothers who smoked throughout preg-
nancy; notably, some of these changes persisted well
into childhood. These altered methylations occurred
in and around genes, including BMP4, PRDM8, DLGAP2,
and NRP2, associated with key developmental pro-
cesses. As with any large-scale project, the results are
just the beginning; future studies can draw upon the
work of Joubert et al. to develop new hypotheses aimed
at better understanding the complexities of the fetal
environment.erican Journal of Human Genetics 98, 593–594, April 7, 2016 593
Peering at the Neandertal Y
Mendez et al., p. 728
A large body of research suggests that introgression
occurred between early modern humans and Neandertals.
With each new discovery, however, comes a litany of new
questions about when and where these meetings took
place, as well as how these events might have shaped hu-
man history. Although many groups have analyzed Nean-
dertal autosomal DNA andmtDNA, to date, available infor-
mation regarding the Neandertal Y chromosome has been
minimal. In this issue, Mendez et al. report the results of
an exome-capture study of theY chromosome fromaNean-
dertal from El Sidron, Spain. Their analyses place this line-
age as an outgroup to modern humans’ Y chromosomes
with a time to most recent common ancestor of ~588,000
years ago. This is nearly twice as long as that of any previ-
ously identified extant modern human lineages and fits
with estimates of species’ divergence. Perhapsmore intrigu-
ingly, Mendez et al. identified several missense changes in
genes whose protein products encodeminor histocompati-
bility antigens.Might these changeshave contributed toge-
netic isolation of the two species? As with other studies of
ancient humans, this study raises several questions; with
recent advances in technology, however, one can hope
that the answers won’t be too far behind.594 The American Journal of Human Genetics 98, 593–594, April 7, 2A Spectrum of PDE10A Variation
Diggle et al., p. 735; Menacci et al., p. 763
In this issue, two groups studying two different genetic
disorders converge upon the same gene, PDE10A. In
one study, Menacci et al. identified de novo mutations
in children with chorea, a hyperkinetic movement disor-
der. Diggle et al., by contrast, arrived at PDE10A through
their study of families affected by an autosomal-
recessive hyperkinetic movement disorder. PDE10A be-
longs to the phosphodiesterase family, a class of
proteins that dampen cAMP- and cGMP-mediated
intracellular signaling. Together, the work of Menacci
et al. and Diggle et al. implicates aberrant cAMP
signaling in both dominant and recessive forms of
movement disorders. Curiously, both groups identi-
fied only missense mutations; further work will be
needed for gaining a clear understanding of the different
allelic effects. Given its selective localization in the
striatum, PDE10A is currently a lead target for the
treatment of a variety of disorders, including Hun-
tington and Parkinson diseases, in which affected indi-
viduals display hyperkinetic movement. There is hope,
then, that therapeutic intervention might be possible
for individuals harboring a spectrum of PDE10A
mutations.016
